Bristol-Myers Squibb Company

(New York Stock Exchange)
Back to all articles
Bullish +65

Bristol Myers Squibb stock extends Camzyos evidence in adolescents

Clinical trial results Drug approval AI-generated analysis

πŸ“ˆ Bristol Myers Squibb presented 56-week Phase 3 SCOUT-HCM trial data showing a mean 48.1 mmHg reduction in Valsalva left ventricular outflow tract gradient for adolescents with symptomatic obstructive hypertrophic cardiomyopathy.

πŸ‘Ά The study included 44 patients aged 12 to under 18, with continuous Camzyos treatment or a switch from placebo at week 28 demonstrating similar efficacy in reducing the left ventricular outflow tract gradient.

βœ… No patient experienced a left ventricular ejection fraction below 50 percent during the 56-week evaluation, indicating maintained cardiac function across the treatment groups.

πŸ›‘οΈ Safety data showed five treatment-related adverse events and two serious events in the continuous-treatment group, with no serious events recorded in the crossover group during its active-treatment period.

πŸ“œ The U.S. Food and Drug Administration approved Camzyos for pediatric patients weighing at least 30 kilograms in September 2026, validating the drug's use in this new demographic.

πŸ—“οΈ Bristol Myers Squibb plans to present additional clinical and real-world evidence regarding Camzyos at the American Heart Association Scientific Sessions through November 9.

πŸ’° The stock traded at 55.50 euros on Lang & Schwarz on November 9, 2026, following the presentation of positive pediatric trial results.

Bullish Signals
  • Bristol Myers Squibb demonstrated strong efficacy in adolescents with symptomatic obstructive hypertrophic cardiomyopathy, achieving a mean 48.1 mmHg reduction in Valsalva left ventricular outflow tract gradient after 56 weeks of continuous Camzyos treatment.
  • The Phase 3 SCOUT-HCM trial results strengthen the evidence base for Camzyos in a newly eligible pediatric patient segment, following FDA approval for patients weighing at least 30 kilograms in September 2026.
  • Patients who switched from placebo to Camzyos at week 28 achieved similar reductions in the left ventricular outflow tract gradient, confirming the drug's efficacy regardless of prior treatment exposure.
  • The trial reported meaningful improvements in several secondary endpoints without any patient experiencing a decline in left ventricular ejection fraction below 50 percent during the 56-week evaluation.
Risk Factors
  • The small trial population of only 44 patients may limit the generalizability of the results and necessitate further studies to confirm efficacy and safety in a broader adolescent population.
  • Continuing safety monitoring remains relevant for expectations regarding uptake, as the study included five treatment-related adverse events and two serious events in the continuous-treatment group.
Full Analysis
Bristol Myers Squibb presented new 56-week data from the Phase 3 SCOUT-HCM trial on Friday, November 6, at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions in Chicago. The study focused on adolescents aged 12 to under 18 with symptomatic obstructive hypertrophic cardiomyopathy, extending the drug's cardiovascular development story for this pediatric segment. Continuous treatment with Camzyos (mavacamten) produced a mean reduction of 48.1 mmHg in the Valsalva left ventricular outflow tract gradient after 56 weeks. Patients who switched from placebo to Camzyos at week 28 achieved similar reductions, while meaningful improvements were observed in several secondary endpoints without any patient experiencing a left ventricular ejection fraction below 50 percent. The U.S. Food and Drug Administration approved Camzyos for pediatric patients weighing at least 30 kilograms in September 2026. This expanded follow-up strengthens the evidence base for the newly eligible patient segment, though the small trial population of 44 patients and the need for continuing safety monitoring remain relevant factors for future uptake expectations. Bristol Myers Squibb plans to present additional data covering clinical and real-world evidence at the American Heart Association Scientific Sessions through November 9. The company's stock traded at 55.50 euros on Lang & Schwarz on Monday, November 9, 2026, reflecting market reaction to the positive pediatric trial results.